Compare Gemini Space Station Inc (GEMI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Gemini Space Station Inc trades at $3.84 (market cap $531.57M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 9.2× Gemini Space Station Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 15 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GEMI | TVTX | |
|---|---|---|
Market Cap | $531.57M | $4.88B |
Volume | 1,676,380 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $22.36 | $67.52 |
52-Week Low | $3.54 | $26.79 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $510.60M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.10, down 0.24% with bearish technical signals despite recent price surges. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings estimates with a net loss of -$517 million. Analyst consensus shows mixed sentiment with a $5.25 price target, while technical indicators show oversold conditions with RSI at 10.68.
The stock faces significant fundamental challenges with negative profit margins and cash burn, though revenue diversification shows promise. Near-term catalysts include SEC regulatory developments for tokenized stocks, but legal risks and persistent losses create substantial downside potential for investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
